These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3818330)

  • 21. A neonatal mouse model of intestinal perforation: investigating the harmful synergism between glucocorticoids and indomethacin.
    Gordon PV; Herman AC; Marcinkiewicz M; Gaston BM; Laubach VE; Aschner JL
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):509-19. PubMed ID: 18030227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypermagnesemia and intestinal perforation following antacid administration in a premature infant.
    Brand JM; Greer FR
    Pediatrics; 1990 Jan; 85(1):121-4. PubMed ID: 2296480
    [No Abstract]   [Full Text] [Related]  

  • 23. Predictors of ductal closure and intestinal complications in very low birth weight infants treated with indomethacin.
    Madan J; Fiascone J; Balasubramanian V; Griffith J; Hagadorn JI
    Neonatology; 2008; 94(1):45-51. PubMed ID: 18196930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
    Fakhraee SH; Badiee Z; Mojtahedzadeh S; Kazemian M; Kelishadi R
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Oct; 9(5):399-403. PubMed ID: 17937843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants.
    Cherif A; Jabnoun S; Khrouf N
    Am J Perinatol; 2007 Jun; 24(6):339-45. PubMed ID: 17564958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation.
    Sperandio M; Beedgen B; Feneberg R; Huppertz C; Brüssau J; Pöschl J; Linderkamp O
    Pediatrics; 2005 Dec; 116(6):1361-6. PubMed ID: 16322159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postnatal dexamethasone for lung disease of prematurity.
    Gordon PV
    N Engl J Med; 2004 Jun; 350(26):2715-8; author reply 2715-8. PubMed ID: 15218578
    [No Abstract]   [Full Text] [Related]  

  • 28. [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants].
    Monset-Couchard M; Dias-Mançano D; Murat I; Relier JP
    Pediatrie; 1983 Sep; 38(6):365-77. PubMed ID: 6364030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic image (232). A neonate with bilious vomiting].
    de Vries A; van Rijn RR
    Ned Tijdschr Geneeskd; 2005 Mar; 149(12):637. PubMed ID: 15813431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is oral indomethacin effective in treatment of preterm infants with patent ductus arteriosus?
    Satar M; Yapicioğlu H; Narli N; Ozbarlas N; Küçükosmanoğlu O; Tutak E
    Turk J Pediatr; 2004; 46(2):137-41. PubMed ID: 15214742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibuprofen vs indomethacin for treatment of PDA in preterm infants.
    Gupta P
    Indian Pediatr; 1998 Mar; 35(3):292-3. PubMed ID: 9707894
    [No Abstract]   [Full Text] [Related]  

  • 32. Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams.
    Supapannachart S; Khowsathit P; Patchakapati B
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S87-92. PubMed ID: 10730525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NSAID-induced small bowel perforation.
    Forshaw MJ; Zayyan K; Power DM
    ANZ J Surg; 2001 Apr; 71(4):255-6. PubMed ID: 11355739
    [No Abstract]   [Full Text] [Related]  

  • 34. Intestinal perforations after enteral administration of indomethacin in premature infants.
    Kühl G; Seyberth HW
    J Pediatr; 1986 Feb; 108(2):327-8. PubMed ID: 3944724
    [No Abstract]   [Full Text] [Related]  

  • 35. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome.
    Al Za'abi M; Donovan T; Tudehope D; Woodgate P; Collie LA; Charles B
    Ther Drug Monit; 2007 Dec; 29(6):807-14. PubMed ID: 18043480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indomethacin therapy for patent ductus arteriosus in premature infants: efficacy of a dosing strategy based on a second-dose peak plasma indomethacin level and estimated plasma indomethacin levels.
    O'Donovan DJ; Fernandes CJ; Nguyen NY; Adams K; Adams JM
    Am J Perinatol; 2004 May; 21(4):191-7. PubMed ID: 15168317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible precursor of diaphragm disease in the small intestine.
    Going JJ; Canvin J; Sturrock R
    Lancet; 1993 Mar; 341(8845):638-9. PubMed ID: 8094872
    [No Abstract]   [Full Text] [Related]  

  • 38. Spontaneous localized intestinal perforation and intestinal dilatation in very-low-birthweight infants.
    Koshinaga T; Gotoh H; Sugito K; Ikeda T; Hagiwara N; Tomita R
    Acta Paediatr; 2006 Nov; 95(11):1381-8. PubMed ID: 17062464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus.
    Evans M; Bhat R; Vidyasagar D; Patel M; Hastreiter A
    Pediatr Pharmacol (New York); 1981; 1(3):251-8. PubMed ID: 7346745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes.
    Laughon M; Bose C; Clark R
    J Perinatol; 2007 Mar; 27(3):164-70. PubMed ID: 17251985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.